Chemagis Ltd.

Teva Pharmaceutical Industries Limited

Astra Lakemedel Aktiebolag

Agis Industries (1983) Ltd.

Chemiagis, Ltd.

Agis Industries Ltd.

Joseph Kaspi

Oded Arad

Ori Lerman

Vladimir Naddaka

Michael Brand

Mohammed Alnabari

Shady Saeed

Oded Friedman

Edna Danon

Lior Zelikovitch

Yana Sery

Alexander Weisman

Itai Adin

Guy Davidi

Dionne Montviliski

Shadi Saeed

Moty Shookrun

Ronit Chen

Olga Etlin

Deby Yigal

Ilana Lavon

Chalil Abu-Gnim

Amira Zeevi

Erez Gal

Boris Freger

Lei Zhang

Haim Yellin

Eduard Schwartz

Stephen Cherkez

David Ladkani

Moshe Arkin

Yanling Wang

Eyal Klopfer

Elena Ostrovsky

Moshe Bentolila

He Xungui

Michael Tennenbaum

Liu Xing

Zinovi Itov

Yuang Wang

Dov Brenner

Gad Salemnick

Clara Schoenberger

Jacob Vaya

Julia Ditkovitch

Yana Seryi

Huang Anli

Yuri Futerman

Tang Wensheng

Irina Gribun

Chaim Ashkenazi

Ada Salman

Zhang Xingzhong

Meital Shiffer

Ariana Segal

Yaacov Rubinsztain

Rina Uzan

Chalil Abu Gnim

Orna Kurlat

Jael Lexner

Gidon Pilarski

Naim Menashe

Eliezer Adar

Stephan Cherkez

David Sondack

Yoav Racchav

Iosef Manascu

Jael Lexmer

Tamir Fizitzki

Vladimir Nadaka

Carmen Iustain

Shifra Katz

Yoav Raechav

Provided are novel salts of 2-(1-azabicyclo-[2.2.2]oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one, methods of using such salts, and processes for producing such salts.

Palonosetron salts and processes for preparation and purification thereof

Derivatives of 1,2-benzisoxazole-3-methanesulfonic acid, which are non-hygroscopic and non-hydrated and their use as intermediates from the preparation of zonisamide are disclosed. Further disclosed are processes of preparing zonisamide from these 1,2-benzisoxazole-3-methanesulfonic acid derivatives, processes of preparing exemplary 1,2-benzisoxazole-3-methanesulfonic acid derivatives and crystalline forms of exemplary 2-benzisoxazole-3-methanesulfonic acid derivatives. A novel process of preparing zonisamide is also disclosed.

Derivatives of 1,2-benzisoxazole-3-methane sulfonic acid as novel intermediates for the synthesis of zonisamide

The present invention provides a process for preparing highly pure Temozolomide base which includes recovery from the purification mother liquors by using an anionic exchange resin. By treating Temozolomide hydrochloride with a mixture of an organic acid, a water miscible organic solvent, and water, Temozolomide free base is obtained in an acidic medium. Due to the high sensitivity of Temozolomide to basic pH values the recovery-including process is especially advantageous because it enables obtaining high yields of highly pure Temozolomide base in acidic conditions. The process for producing Temozolomide base includes hydrolysis of the starting material 8-cyano-3-methyl-[3H]-imidazo[5,1-d]-tetrazin-4-one in acidic medium to obtain highly pure Temozolomide hydrochloride in high yield.

Process for preparing temozolomide

The present invention provides a crystalline donepezil maleate, which is used as an intermediate in the preparation of donepezil hydrochloride. Also provided are novel processes for producing same in substantially pure form and a process for producing pharmaceutically pure amorphous donepezil hydrochloride therefrom.

Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride

A novel process for preparing (2&#x3b2;,3&#x3b1;,5&#x3b1;,16&#x3b2;,17&#x3b2;)-17-acetoxy-3-hydroxy-2-(4-morpholinyl)-16-(1-pyrrolidinyl) androstane, a known intermediate in the synthesis of the skeletal muscle relaxant rocuronium bromide, is disclosed.

Processes for the preparation of rocuronium bromide and intermediates thereof

The present invention provides a novel montelukast intermediate and a simple and straightforward process for preparing it. According to the present invention, by using this intermediate and the process, essentially as described herein, montelukast acid and salts thereof are obtained.

Process for preparing 1-(mercaptomethyl)cyclopropaneacetic acid, a useful intermediate in the preparation of montelukast and salts thereof

An amorphous form of montelukast sodium and a montelukast sodium lactose co-precipitate, processes for producing same, pharmaceutical compositions containing same and methods of treatment utilizing same are disclosed.

Stable amorphous forms of montelukast sodium

Provided is a method for preparing letrozole, which includes reacting an activated bis-(4-cyanophenyl)-methane with a triazole to produce letrozole, and, optionally, purifying the letrozole. Also provided are highly pure letrozole, and a method of purifying letrozole, which method includes precipitating letrozole, e.g., by selective precipitation from a reaction mixture and/or by subjecting the letrozole to one or more crystallizations.

Letrozole production process

The present invention provides a process for preparing highly pure montelukast and salts thereof by reacting the side-chain precursor 1-(mercaptomethyl)-cyclopropaneacetic acid with 2-(2-(3S)-(3-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3-(methanesulfonyloxypropyl)phenyl-2-propanol in a solvent mixture containing a base.

Process for preparing montelukast and salts thereof

A novel process for preparing highly pure cilostazol, effected by reacting 6-hydroxy-3,4-dihydroquinolinone and 5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole in the presence of a hydrated inorganic base, is disclosed. Further disclosed is highly pure cilostazol, and particularly highly pure cilostazol that is substantially free of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-1-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butyl ]-3,4-dihydro-1H-quinolin-2-one.

Highly pure cilostazol and an improved process for obtaining same

A novel process is disclosed for producing Imatinib, using the precursor 2-chloro-4-(3-pyridyl)-pyrimidine, thus improving Imatinib preparation via an alternative synthetic route, avoiding the use of the toxic reagent cyanamide.

Process for preparing Imatinib

The present invention provides a process for preparing 4-amino-1-isobutyl-1H-imidazo[4,5-c]quinoline (Imiquimod) of formula (I). The process comprises heating 4-chloro-1-isobutyl-1H-imidazo[4,5-c]quinoline of formula (II) with formamide, and optionally with bubbling of gaseous ammonia to afford Imiquimod of formula (I). According to the present invention, by using this process and novel purification methods, essentially as described herein, highly pure Imiquimod is obtained.

Process for preparing Imiquimod

The present invention provides a crystalline halobetasol propionate selected from the group consisting of halobetasol propionate having crystalline Form I characterized by power X-ray diffraction peak positions and intensities as set forth in Table 1 herein, halobetasol propionate having crystalline Form II characterized by power X-ray diffraction peak positions and intensities as set forth in Table 2 herein, halobetasol propionate having crystalline Form III characterized by power X-ray diffraction peak positions and intensities as set forth in Table 3 herein, halobetasol propionate having crystalline Form IV characterized by power X-ray diffraction peak positions and intensities as set forth in Table 4 herein, halobetasol propionate having crystalline Form V characterized by power X-ray diffraction peak positions and intensities as set forth in Table 5 herein, and halobetasol propionate having crystalline Form VI characterized by power X-ray diffraction peak positions and intensities as set forth in Table 6 herein.

Crystalline forms of halobetasol propionate

The invention provides a process for preparing 1-methylindazole-3-carboxylic acid of formula (I): which comprises reacting a methylating agent with indazole-3-carboxylic acid of formula (VI): in the presence of an alkaline earth metal oxide or alkoxide in an appropriate solvent. Also provided is a process for producing Granisetron, using the method of the present invention for producing 1-methylindazole-3-carboxylic acid.

Process for preparing 1-methylindazole-3-carboxylic acid

The invention provides a process for the preparation of a compound of the formula 6 comprising the hydrolysis and decarboxylation of a compound of the formula 5 according to the reaction:wherein R and Rindependently a C-Calkyl group or an aralkyl group.

Process for the preparation of donepezil

Growing community of inventors

Givatayim, Israel

Joseph Kaspi